Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Stock Chart & Stats
$9.52
$0.30(1.54%)
At close: 4:00 PM EST
$9.52
$0.30(1.54%)
Day’s Range― - ―
52-Week Range$5.90 - $29.61
Previous CloseN/A
Volume216.17K
Average Volume (3M)2.39M
Market Cap
$710.68M
Enterprise Value-$313.82M
Total Cash (Recent Filing)$861.20M
Total Debt (Recent Filing)$9.90M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Nov 11, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding73,417,595
10 Day Avg. Volume2,635,323
30 Day Avg. Volume2,386,482
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.44
Enterprise Value/Revenue-0.84
Enterprise Value/Gross Profit-0.84
Enterprise Value/Ebitda2.71
Forecast
1Y Price Target
$19.07Price Target Upside100.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentVepdeg showed meaningful quality-of-life gains in previously treated ER+/HER2- ESR1 mutant advanced breast cancer.
Pipeline PotentialThe gross pipeline value increased by $100 million to reflect ARV-102’s growing potential in neurodegeneration.
Share Repurchase ProgramA $100mn share repurchase program is being initiated to support value creation.
Bears Say
Commercialization UncertaintyThe out-licensing plan for the breast cancer drug vepdegestrant introduces significant uncertainty around the timing of commercialization and by whom.
Competitive LandscapeRapidly evolving competitive landscape for HR+/HER2- mBC puts vepdegestrant at increasing risk of obsolescence.
Market Penetration ExpectationsThe vepdegestrant drug launch has been pushed to 2028, with lowered peak market penetration expectations in the US and EU.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $5.90 and its highest was $29.61 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $710.68M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Nov 11, 2025 which is in 23 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Aug 06, 2025. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.931 by $0.091.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.71.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 73,417,595 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.931. Following the earnings report the stock price went down -15.506%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
Arvinas Holding Company Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.07 (100.32% Upside)
$19.07 (100.32% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 853.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $226.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.79%
12-Months-Change
Fundamentals
Return on Equity
-35.41%
Trailing 12-Months
Asset Growth
-28.94%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress and achievements in clinical trials and partnerships, notably with Novartis and the NDA submission for Vepdeg. However, challenges such as revenue decline, restructuring costs, and issues with the Pfizer collaboration were noted. The sentiment is balanced between positive developments and significant challenges.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$19.07
▲(100.32% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
2.92% Insiders
20.41% Mutual Funds
0.16% Other Institutional Investors
63.79% Public Companies and
Individual Investors